clinical and functional consequences associated to a pkp2 founder

24
Session: Advances in genetics of cardiomyopathies Clinical and functional consequences associated to a PKP2 founder mutation in north-west Spain Presenter: Lorenzo Monserrat Paris, 28 Aug 2011 A. Diez-Juan , MF. Ortiz, L. Perez-Alvarez, R. Barriales-Villa, DA. Garcia, J. Moncayo-Arlandi, X. Fernandez, L. Nunez, L. Monserrat

Upload: others

Post on 11-Feb-2022

5 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Clinical and functional consequences associated to a PKP2 founder

Session: Advances in genetics of cardiomyopathies

Clinical and functional consequences

associated to a PKP2 founder mutation in

north-west Spain

Presenter: Lorenzo Monserrat

Paris, 28 Aug 2011

A. Diez-Juan , MF. Ortiz, L. Perez-Alvarez, R. Barriales-Villa, DA. Garcia, J.

Moncayo-Arlandi, X. Fernandez, L. Nunez, L. Monserrat

Page 2: Clinical and functional consequences associated to a PKP2 founder

Potential conflicts of interest

Lorenzo Monserrat:

Promoter and Stockholder:

Health in Code

Page 3: Clinical and functional consequences associated to a PKP2 founder

•Primary and inherited affection of the myocardium(estimated

prevalence 1:5000 )

•Progressive replacement of right ventricular myocardium with

adipose and fibrous tissue (mainly RV, but also LV)

ARVC

Page 4: Clinical and functional consequences associated to a PKP2 founder

DESMOSOMAL GENES

www.e-heart.org

Page 5: Clinical and functional consequences associated to a PKP2 founder

•25 unrelated index cases with ARVC from A Coruña

(Galicia-Spain)

•Sequence analysis of 4 main desmosomal genes:

•Plakophilin-2 (PKP2)

•Desmoplakin (DSP)

•Desmoglein-2 (DSG2)

•Desmocollin-2 (DSC2)

COHORT

Page 6: Clinical and functional consequences associated to a PKP2 founder

GEOGRAPHICAL DISTRIBUTION

Page 7: Clinical and functional consequences associated to a PKP2 founder

•10 mutations (9 novel) in 17 of 25 pts 68%

•4 pts complex genotypes 16%

•1 homozygous

•1 compound heterozygous

•2 doble heterozygous

•3 mutations in more than 1 proband

•S329RfsX351 in PKP2 (9 cases)

•R375X in DSC2 (2 cases)

•C813R in DSG2 (2 cases)

GENETIC STUDIES

Page 8: Clinical and functional consequences associated to a PKP2 founder

PROBAND PKP2 DSP DSC2 DSG2

1 S329RfsX351

2 S329RfsX351

3* S329RfsX351

E624D

4* S329RfsX351 K468Q

5 S329RfsX351

6* S329RfsX351 R375X

7 S329RfsX351

8 S329RfsX351

9 S329RfsX351

10* R375X (H)

11 IVS11+2T>C

12 M589T

13 IVS9-1G>C

14 R1945C

15 R907L

16 C813R

17 C813R

* Complex genotypes

Page 9: Clinical and functional consequences associated to a PKP2 founder

18 carriers

8 non carriers

49 without

genetic study

9 families

S329RfsX351 – PKP2

8 ARVC

7 possible ARVC

3 not affected or healthy

1 possible ARVC

7 not affected or healthy

1 ARVC

1 possible ARVC

3 not affected or healthy,

44 without phenotypic study

Page 10: Clinical and functional consequences associated to a PKP2 founder

Events in mutation carriers

2 Sudden deaths

4 Appropiate ICD shocks

1 Stroke related death

2 Strokes without death

Events in relatives without genetic study

3 Sudden deaths

2 Stroke related deaths

1 Stroke without death

EVENTS

Page 11: Clinical and functional consequences associated to a PKP2 founder

SD

SD SD

aSD

aSD

ICDs

ICDs

ICDs

ICDs

HCM HCM

Stroke Stroke

x2

Stroke

Stroke

Stroke

Page 12: Clinical and functional consequences associated to a PKP2 founder

Table - Genetic and clinical characteristics of S329RfsX351-PKP2 carriers

Page 13: Clinical and functional consequences associated to a PKP2 founder
Page 14: Clinical and functional consequences associated to a PKP2 founder

Table - Clinical characteristics of relatives without genetic diagnosis who had

adverse events

Page 15: Clinical and functional consequences associated to a PKP2 founder

Fressart et al. Europace 2010;12:861-868

300

healthy

controls

Page 16: Clinical and functional consequences associated to a PKP2 founder

?

Page 17: Clinical and functional consequences associated to a PKP2 founder

PKP2 –

S329RfsX351

•Costa da Morte

(Death coast)

FOUNDER

EFFECT

Page 18: Clinical and functional consequences associated to a PKP2 founder

PKP 2: Constructions

S329fsX351

(pb4086)

Armadillo domain Variable domain

N

´ C

´

hPKP2 V5

Esmeral V5 mPKP2

Esmeral V5 mPKP2

(Control)

Esmeral V5

Experimentals

S329fsX351

EXT

INT

INT

Plakophilin 2

S329fsX351

Control

Page 19: Clinical and functional consequences associated to a PKP2 founder

H9C2

Rat ventricular cardiomyocytes

HL-1

Mouse atrial cardiomyocytes

Neonatal Cardiomyocytes

Rat ventricular cardiomyocytes

Esmeral V5

mPKP2

Esmeral V5 mPKP2

Esmeral V5

hPKP2 V5

S329fsX351

Esmeral V5 mPKP2

S329fsX351

Lentiviral vector

Page 20: Clinical and functional consequences associated to a PKP2 founder

hPKP2

-v5

hPKP2

-v5 Control Control

Cytoplasmic Nuclear

v5

hPKP2

-v5

hPKP2

-v5 Control Control

Cytoplasmic Nuclear

PKP2

hPKP2 V5 mPKP2

Control Control hPKP2-v5 hPKP2-v5

HL-1

Mouse Atrial Cardiomiocytes

α- Tubulin α- Tubulin

Anti V5 Anti C-term

Page 21: Clinical and functional consequences associated to a PKP2 founder

HL-1

Mouse Atrial Cardiomiocytes

Control hPKP2-v5 Control hPKP2-v5

γ-catenin Desmoplakin

Page 22: Clinical and functional consequences associated to a PKP2 founder

Neonatal rat

ventricular

cardiomyocytes

Control hPKP2-v5

Anti-v5

Anti-PKP2

↑↑ PPAR-γ (Adipogenic factor)

↑ TGF-β2 and TGF β3 (Fibrosis factors)

↑ Vimentin (Adipogenic marker)

Fibrosis

factors

Adigogenic

marker

hPKP2 V5

Page 23: Clinical and functional consequences associated to a PKP2 founder

CONCLUSIONS

•Mutations in 70% of ARVC cases

•S329RfsX351-PKP2 is a pathogenic mutation

associated with the development of ARVC

•Founder mutation in Galicia

•Incomplete penetrance in young carriers

•Severe expression in cases with additional

pathogenic mutations

•Arrhythmic sudden death and strokes

•LV involvement relatively common

Page 24: Clinical and functional consequences associated to a PKP2 founder

CONCLUSIONS

•Functional studies:

•PKP2 not only a structural protein

•Nuclear localization of mutant PKP2 could

be responsible of anomalous cardiomyocyte

gene expression

•Support for a role for immunofluorescence

studies in the diagnosis of ARVC (Asimaki et al)